Sanofi Joins Growing Group of Pharmas Pulling Back From UK Merck, Eli Lilly and AstraZeneca have similarly suspended or outright canceled investments in the U.K. in the past week after a sizeable increase in a mandatory levy in the region…
EASD 2025: Orforglipron in Focus, the Case for Cardiovascular Benefits, More While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this week, experts told BioSpace the conference will also provide important insights…
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due…
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior…
FDA grants Breakthrough Therapy Designation to Raludotatug Deruxtecan for CDH6+ platinum-resistant ovarian and related cancers previously treated with bevacizumab Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment…
EU approves first oral GLP-1 RA to cut cardiovascular risk Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular…
People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being Novo Nordisk today announced results from the US-based INFORM survey of people taking semaglutide for weight management (Wegovy®), at the European Association for the Study of Diabetes…
Cholera Deaths Rise for Second Year Despite Available Prevention and Treatment The World Health Organization (WHO) has published its global cholera statistics for 2024, showing an increase in both the number of people who fell sick and died from the disease.…
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created…
Modeyso™ (Dordaviprone) Gains Inclusion in NCCN Clinical Practice Guidelines, Marking a Milestone in the Treatment of H3 K27M-Mutant Diffuse Glioma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced a pivotal development for its oncology portfolio with the inclusion of Modeyso™ (dordaviprone) in…
Novartis to Acquire Tourmaline Bio, Advancing Cardiovascular Pipeline with Pacibekitug for ASCVD Novartis today revealed a major step forward in its cardiovascular disease (CVD) strategy with the announcement that it has entered into an agreement to acquire Tourmaline Bio, Inc.…
Cascade Bio Secures $6 Million to Advance Biocatalyst Innovation and Transform Biomanufacturing In a world grappling with climate change, supply chain disruptions, and the growing demand for sustainable manufacturing, biotechnology companies are racing to create alternatives to petrochemical-based production. Cascade…